Visiongain has launched a new pharma report: Global Anti-obesity Drugs Market Forecast 2020-2030: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs.
The Global Anti-obesity Drugs Market is segmented into mechanism of action, duration of action, prescription vs. OTC and innovator vs. generic drugs. Mechanism of action (MoA) is further classified as Incretin mimetics/GLP-1 agonists, Lipase inhibitors, Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics and others. Most of the anti-obesity drugs have gone off-patent and thus this drug market is also marketed in to two markets as Innovator and Branded drugs. In addition, the market is marketed as prescription and over-the-counter (OTC) based on need for prescription for dispensing the drug.
To request a overview of this report please contacts Sara Peerun at firstname.lastname@example.org or refer to our website:@ https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2020-2030/
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 285-page report you will receive 146 tables and 137 figures– all unavailable elsewhere.
The 285-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
- Global Anti-obesity Drugs Market forecast from 2020-2030
- Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:
• Incretion mimetics/GLP-1 agonists
• Lipase Inhibitors
• Serotonin receptor agonists
• Sympathomimetic-GABA receptor agonists
- Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Duration of Therapy:
• Long-term Drugs
• Short-term Drugs
- Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Innovator vs Generic Drugs:
• Generic Drugs
- Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Prescription vs OTC:
• Prescription Drugs
- This report discusses and provides revenue forecasts from 2020-2030 for selected anti-obesity drugs:
- This report provides individual revenue forecasts from 2020-2030 for these regional and national markets:
• EU5: Germany, France, Spain, Italy, UK
• BRIC: Brazil, Russia, China, India
Download a Sample Report with Table of Contents and Figures by clicking here @https://www.visiongain.com/report/global-anti-obesity-drugs-market-forecast-2020-2030/
Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs.
- Our study discusses the selected leading companiesthat are the major players in the anti-obesity drugs market:
• Arena Pharmaceuticals
• Carmot Therapeutics
• Currax Pharmaceuticals LLC
• ERX Pharmaceuticals
• GlaxoSmithKline (GSK)
• Hanmi Pharmaceutical
• LNC Therapeutics
• Novo Nordisk
• Rhythm Pharmaceuticals, Inc.
• Scohia Pharma, Inc.
• Sinil Pharmaceutical Co., Ltd
- This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.
- This report gives an overview of pricing and reimbursementin the US and EU.
- This report provides aSWOT Analysisof the global anti-obesity drugs market.
- Key questions answered by this report:
• How is the anti-obesity drugs market evolving?
• What is driving and restraining anti-obesity drugs dynamics?
• How will each anti-obesity drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2030?
• How will market shares of each anti-obesity drugs submarket develop from 2020-2030? Which individual technologies will prevail and how will these shifts be responded to?
• Which anti-obesity drugs submarket will be the main driver of the overall market from 2020-2030?
• How will political and regulatory factors influence regional anti-obesity drugs markets and submarkets?
• Will leading national anti-obesity drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy?
• How will market shares of the national markets change by 2030 and which nation will lead the market in 2030?
• Who are the leading players and what are their prospects over the forecast period?
• How will the sector evolve as alliances form during the period between 2020 and 2030?
Visiongain’s study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Find More Other Industry Research Reports by Visiongain:
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:
Visiongain is one of the fastest-growing and most innovative independent market research company in Europe, the company comprises over 400+ analysts and consultants, adding more than 1400 market research reports to its vast database each year. These reports offer in-depth analysis on 18 industries worldwide. With the help of an interactive market intelligence platform, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Phone: +44 (0) 20 7549 9987.